Search research articles
Contact Us
Filters
Showing results (121-130 of 162) with videos related to
Page
of 17
Sort By:
Cancer
|
October 15, 1991
DNA content flow cytometry as a prognostic factor for node-positive breast cancer. The role of multiparameter ploidy analysis and specimen sonication
T E Witzig, N J Gonchoroff, T Therneau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2005
The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)
K M Wasan, P E Goss, P H Pritchard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2000
American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel
B E Hillner, J N Ingle, J R Berenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1996
Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials
K S Albain, S R Green, A S Lichter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 24, 2005
A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study
C X Ma, P Steen, K M Rowland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 1999
Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer
J N Ingle, V J Suman, P A Johnson, et al.
Journal of the National Cancer Institute
|
December 21, 1994
p53 gene expression in node-positive breast cancer: relationship to DNA ploidy and prognosis
J M Cunningham, J N Ingle, S H Jung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 1998
Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins
J B Lawrence, C A Conover, T C Haddad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 1993
DNA ploidy and percent S-phase as prognostic factors in node-positive breast cancer: results from patients enrolled in two prospective randomized trials
T E Witzig, J N Ingle, D J Schaid, et al.
Cancer
|
June 15, 1996
A pilot evaluation of alternating preoperative chemotherapy in the management of patients with locoregionally advanced breast carcinoma
T M Pisansky, C L Loprinzi, S S Cha, et al.
Page
of 17
Search research articles
Search
Showing results (121-130 of 162) with videos related to
Sort By:
Page
of 17
Cancer
|
October 15, 1991
DNA content flow cytometry as a prognostic factor for node-positive breast cancer. The role of multiparameter ploidy analysis and specimen sonication
T E Witzig, N J Gonchoroff, T Therneau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2005
The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)
K M Wasan, P E Goss, P H Pritchard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2000
American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel
B E Hillner, J N Ingle, J R Berenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1996
Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials
K S Albain, S R Green, A S Lichter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 24, 2005
A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study
C X Ma, P Steen, K M Rowland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 1999
Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer
J N Ingle, V J Suman, P A Johnson, et al.
Journal of the National Cancer Institute
|
December 21, 1994
p53 gene expression in node-positive breast cancer: relationship to DNA ploidy and prognosis
J M Cunningham, J N Ingle, S H Jung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 1998
Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins
J B Lawrence, C A Conover, T C Haddad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 1993
DNA ploidy and percent S-phase as prognostic factors in node-positive breast cancer: results from patients enrolled in two prospective randomized trials
T E Witzig, J N Ingle, D J Schaid, et al.
Cancer
|
June 15, 1996
A pilot evaluation of alternating preoperative chemotherapy in the management of patients with locoregionally advanced breast carcinoma
T M Pisansky, C L Loprinzi, S S Cha, et al.
Page
of 17